

Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Member: Marvin Konstam, M.D.

Committee: Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)

Meeting Date: June 20, 2017

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: The committee will discuss supplemental new drug application (sNDA) 022341 VICTOZA (liraglutide) injection, sponsored by Novo Nordisk, for the proposed additional indication as adjunct to standard treatment of cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk. The topic of this meeting is a particular matter involving specific parties.

I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Consulting	(b) (4) (Competing Firm)	\$0 – 50,000 per year
II. Other Imputed Interests		
Contracts/grants	Janssen Pharmaceuticals (Competing Firm)	\$0 – 50,000 per year

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/
Signature

5/18/2017
Date